Systemic Antibiotics, Antivirals, and Analgesics for Ocular Conditions
When oral medications are needed in eye care
Most eye conditions are managed with topical drops, but certain situations require systemic therapy to reach tissue levels that drops alone cannot achieve. Oral medications are commonly prescribed in optometry for periocular infections such as preseptal cellulitis and dacryocystitis, herpetic eye disease involving the cornea or adnexa, moderate-to-severe meibomian gland dysfunction and ocular rosacea, acute IOP emergencies requiring rapid pressure reduction, and significant ocular or periocular pain that topical measures cannot adequately control. The medication table on this page covers common agents, dosing, contraindications, and monitoring reminders for each of these categories.
Oral antibiotics: treating infection vs modulating inflammation
In eye care, oral antibiotics serve two distinct roles. One is short, therapeutic dosing for true infection. The other is longer, sub-antimicrobial dosing to reduce chronic lid and ocular surface inflammation.
- Anti-infective use: Standard or higher-dose therapy is used for adnexal and periocular infections such as preseptal cellulitis, dacryocystitis, or significant internal hordeola. Common first-line choices include cephalexin or amoxicillin-clavulanate, with alternatives chosen based on allergy history, local resistance patterns, and systemic comorbidities. If the ocular surface is involved, topical therapy from the ophthalmic antibiotics section is often layered on.
- Anti-inflammatory use: Low-dose doxycycline (commonly 20 to 50 mg once or twice daily) or pulsed azithromycin can be used as sub-antimicrobial therapy for MGD and ocular rosacea. At these doses, the goal is not bacterial eradication but reduction of lipase activity and matrix metalloproteinase (MMP) mediated inflammation, improved meibum quality, and tear film stabilization, alongside measures in the dry eye plan and eyelid hygiene.
Acetazolamide and oral carbonic anhydrase inhibitors
Acetazolamide (Diamox) and other oral carbonic anhydrase inhibitors (CAIs) are typically reserved for situations where rapid or substantial intraocular pressure reduction is needed beyond what topical therapy can provide. Examples include acute angle-closure, markedly elevated IOP prior to laser or surgery, or advanced disease not controlled despite maximized topical regimens outlined in the glaucoma medications section. Common dosing is 250 mg two to four times daily or 500 mg sustained-release twice daily. Because systemic CAIs can cause paresthesia, fatigue, gastrointestinal upset, metabolic acidosis, electrolyte disturbance, kidney stone risk, and sulfonamide-associated reactions, they are often used as short-term bridge therapy with attention to kidney function, potassium levels, and comorbidities.
Systemic pain control and co-management
For significant ocular or periocular pain, such as post-operative discomfort, HZO-related neuralgia, or severe corneal injury, systemic analgesics may be used alongside topical measures discussed in the pain management section. Oral NSAIDs such as ibuprofen or naproxen are often effective for prostaglandin-mediated inflammatory pain, while acetaminophen may be preferred when NSAIDs are contraindicated due to ulcer history, renal disease, or anticoagulation. For neuropathic pain, coordination with the patient's primary care or pain team is appropriate. Documentation is clearer when it distinguishes whether a medication is being used for infection, inflammation control, IOP reduction, or analgesia.